Organogenesis Holdings Inc.

Organogenesis Holdings Inc.

ORGONYSE / NASDAQHealthcareSmall cap

$0.77-$0.02 (-2.2%)

Last close · Data as of Nov 20, 2026

Market cap
$319.1M
P/E
8.6x
EV / EBITDA
3.7x
Revenue
$563.0M
Net margin
6.6%
ROCE
11.2%

-84.9% over the last year

Organogenesis Holdings Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-24.3%
3M
-58.0%
6M
-69.7%
1Y
-84.9%
5Y
Hidden
  • This period includes a one-day price step on 28 Feb 2025 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change -$0.02 (-2.2%) from $0.79 to $0.77 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ORGO, bought on each weekday since 2021.

News & filings

What Organogenesis Holdings filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernOperating cash flow was -10.3 million US dollars in fiscal 2025, a year of net profit.

Strengths (1)

  • Operating profit was 36.3 times interest costs.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States.

Read moreShow less

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature. The company also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; and TransCyte, a bioengineered tissue scaffold that promotes burn healing. In addition, it develops ReNu, a cryopreserved suspension, which is in Phase 3 trial, for the management of symptoms associated with knee osteoarthritis; and placental products. The company serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through direct sales representatives and independent agencies. Organogenesis Holdings Inc. is headquartered in Canton, Massachusetts.

Sector
Healthcare
Shares outstanding
231.4M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$319.1M
P/E
8.6x
P/B
1.1x
EV / EBITDA
3.7x
EV / Sales
0.5x
P/S
0.6x
52-week high
$5.87
52-week low
$0.76

Profitability

Operating margin
9.9%
Net margin
6.6%
EBITDA margin
14.7%
ROE
12.3%
ROCE
11.2%
ROIC
10.4%
ROA
6.2%
Asset turnover
0.94

Growth

Revenue
$563.0M
Revenue growth, 1Y
16.8%
Revenue CAGR, 3Y
7.7%
Net profit growth, 1Y
4201.0%
Free cash flow
-$24.5M

Solvency

Current ratio
3.62
Debt / Equity
0.27
Debt / Assets
0.14
CFO / Net profit
-0.28
Cash / Market cap
29.4%

Where the revenue went

Of every $100 of FY2025 revenue, $7 was left as net income.

Organogenesis Holdings Inc. income statement flow, FY2025
Organogenesis Holdings Inc. income statement flow, FY2025: flows
FromToAmount
RevenueCost of revenue$137.5M
RevenueGross profit$425.5M
Gross profitOperating expenses$369.6M
Gross profitOperating income$55.9M
Operating incomePretax income$47.0M
Operating incomeInterest and other expense$8.9M
Pretax incomeTax and other$9.9M
Pretax incomeNet income$37.0M

Revenue and net profit

Revenue grew 16.8% in FY2025; net profit is the dashed line.

Organogenesis Holdings Inc. revenue and net profit by fiscal year
Organogenesis Holdings Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$450.9M$15.5M
FY2023$433.1M$4.9M
FY2024$482.0M$861.0k
FY2025$563.0M$37.0M

Cash flows

FY2025: -$10.3M from operations, -$24.5M free after investment (dashed).

Organogenesis Holdings Inc. operating and free cash flow by fiscal year
Organogenesis Holdings Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$24.9M-$9.0M
FY2023$30.9M$6.6M
FY2024$14.2M$4.2M
FY2025-$10.3M-$24.5M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$563.0M+16.8%1Y
EBITDA
$82.8M+243.4%1Y
Net profit
$37.0M+4,201.0%1Y
Cash from operations
-$10.3M-172.6%1Y
Free cash flow
-$24.5M-685.7%1Y
Revenue CAGR, 3Y
7.7%
Net profit CAGR, 3Y
33.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$563.0M$82.8M$37.0M-$24.5M12.3%+16.8%+4201.0%

Monthly returns

Month-by-month returns of ORGO across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$598.7M
Liabilities$164.8M
Equity$433.9M
Paid-in capital$303.2M
Retained earnings-$3.1M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ORGO highlighted.

P/E against peers

ORGO trades at 8.6x earnings against a peer median of 4.7x (a 85% premium).

  1. Organogenesis Holdings Inc. (this company)8.6x

Not shown (no positive earnings and no EV / Sales): Humacyte, Inc., Rocket Pharmaceuticals, Inc., Fennec Pharmaceuticals Inc., DiaMedica Therapeutics Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Organogenesis Holdings Inc.ORGOthis companyP/E ↑ premium$319.1M8.6x1.1x12.3%3.7x
908 Devices Inc.MASS$333.5M17.1x2.3x13.6%-12.6x
Abeona Therapeutics Inc.ABEO$331.7M4.7x2.1x44.7%3.5x
Humacyte, Inc.HUMA$330.8M-8.1x106.4x-1313.4%-15.5x
Rocket Pharmaceuticals, Inc.RCKT$318.8M-1.4x1.2x-80.5%-1.3x
Fennec Pharmaceuticals Inc.FENC$318.2M-32.7x9.0x-27.5%-37.8x
SIGA Technologies, Inc.SIGA$317.7M13.6x1.6x11.7%6.7x
DiaMedica Therapeutics Inc.DMAC$314.7M—5.6x-58.4%—
Electromed, Inc.ELMD$304.0M40.3x7.0x17.4%26.7x
Peer median—4.7x4.0x-7.9%-1.3x

Year-to-date ROI

ORGO since 1 January, against earlier years.

Historical volatility

ORGO's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Organogenesis Holdings Inc. operating margin by fiscal year
Organogenesis Holdings Inc. operating margin by fiscal year
DateOperating margin
FY20224.9%
FY20232.9%
FY20244.5%
FY20259.9%
LineFY2025
Cost of revenueCost Of Revenue$137.5M
Gross profitGross Profit$425.5M
Operating expensesOperating Expense$369.6M
Research and developmentResearch And Development$44.5M
Selling, general and administrativeSelling General And Administration$326.2M
Other operating expensesOther Operating Expenses-$1.1M
Total expensesTotal Expenses$507.2M
Pretax incomePretax Income$47.0M

Learn while you research

Academy chapters picked for Organogenesis Holdings Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Value InvestingA P/E of 8.6 could be a value opportunity, or a value trap. Know the difference.7 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →